Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-08-21
Butterfly Network, Inc.
Butterfly Network sells handheld single-probe ultrasound devices, cloud workflow software, education, and embedded ultrasound-chip licensing to healthcare customers and partners.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging platform with real optionality
The core probe business is real, but the 2031 upside depends on proving that software, compliance, and Embedded become repeatable revenue engines rather than occasional boosts. The stock can still work, but future returns need execution more than narrative.

Analysis

Thesis
Butterfly can still roughly double equity value by 2031 if it turns a differentiated handheld ultrasound franchise into a higher-quality mix of enterprise workflow, embedded licensing, and regulated care-delivery software; AI expands scan volume, but the real value capture must come from verification, compliance, and distribution.
Last Economy Alignment
Moderately positive: AI should broaden ultrasound use and make Butterfly’s probe-plus-workflow bundle more valuable, but big imaging incumbents and device-agnostic AI limit how much of that value Butterfly can keep.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.1x (from 5 most recent analyses)
Reasoning
The upside case does not require category dominance. It requires Butterfly to keep compounding core probe adoption, attach more enterprise workflow software, and make Embedded, public-sector, and home-care channels repeatable enough that the revenue mix looks less like a device vendor and more like a regulated workflow platform. That can support meaningful equity appreciation, but today’s valuation limits how much rerating can do on its own.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether the probe works; it is whether Butterfly can convert promising adjacencies into repeatable, durable revenue before valuation gravity, larger ultrasound vendors, or slower compliance and procurement cycles pull it back toward being viewed as a premium device company.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.35
They own a real piece of hardware plus the workflow around it, so AI can make more people able to scan while Butterfly still sells the device and the verified record. The risk is that bigger imaging vendors or vendor-neutral AI turn that software layer into a feature unless Butterfly converts compliance, embedded partners, and reimbursement workflows into true toll booths.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$9.31
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case